Mr. Paul Eros brings over 25 years of executive experience in diagnostics to Aqsens Health as a Senior Business Advisor

Mr. Paul Eros has a proven track record of excellence in the in-vitro diagnostics field with expertise from executive management to global marketing, sales and product management. Now he is joining Aqsens Health’s team as a Senior Business Advisor, bringing with him a wealth of experience in commercialization, productization and in market entry strategies. Mr. Eros took the time to answer a few questions about his background, his experiences in the industry, and his role as an advisor at Aqsens Health. 

Could you describe your background in the diagnostics and healthcare industry? 

I have been involved in the diagnostics and health industry since 1982. Initially as a microbiologist, before taking on my first commercial role with Becton-Dickinson (BD) in 1985. That was a good grounding for me in the commercial world and I had the opportunity to work in various roles across the UK and Europe. I left BD in 1999 to join Roche Diagnostics where I spent the next twelve and a half years in various commercial and operational executive roles. After Roche I went on to join Diasorin as Global VP of their newly formed Molecular Diagnostics Division and became a member of the BoD of Diasorin Ireland. In 2017 I joined the Anglo-French Group Novacyt, as Managing Director of their PrimerDesign Division, before becoming head of R&D and Product development, and then Chief Business Officer for the group.

In 2022 I decided to set up my own consultancy firm, Amicon Bio, where I work with SMEs in the LifeScience and Diagnostic sectors, using my many years of experience to help them on their journey towards commercial success. 

What has inspired your long career in this industry? 

I am inspired by innovation in Diagnostics being applied to helping people live long and healthy lives. Whilst the Diagnostics industry is much smaller than some of the related healthcare sectors, its role in guiding treatment and therapy decisions is critical to modern healthcare. The recent COVID pandemic brought the Diagnostics industry into everyone's living rooms, as people grappled with doing their own lateral flow or molecular diagnostic test to understand their infection status. But much of the work in Diagnostics takes place out of the public limelight; whether it's diagnosing cancer, heart disease, meningitis, SEPSIS, or any one of a series of other debilitating and life threatening diseases, the modern healthcare system would not be the same without the power of modern diagnostic tools. 

What is your role as a Senior Advisor at Aqsens? 

As a Senior Business Advisor my role is to advise across a range of areas but most important of these is to leverage my commercial background in the industry to help guide decision making around how to get products to market and into the hands of customers. 

How do you see the potential of Aqsens Health’s E-TRF and biosensors? How could they shape the future of diagnostics?

Having the right, accurate diagnostic result at the right time to make informed decisions about patient therapy and care pathways is vital to improving patient outcomes. Whether this is in a highly specialized central laboratory or a testing site in a remote, low resource setting, getting diagnostic tools into the hands of treating clinicians is vital to improving health outcomes. I think the  E-TRF and biosensors being developed by Aqsens Health will have a significant impact upon the diagnosis of diseases and in the process revolutionize and democratize  healthcare for many.

What do you look forward to in working with Aqsens Health?

I look forward to seeing products that make a difference being delivered into the hands of healthcare professionals across the globe. 

Thank you to Mr. Eros for answering our questions, we look forward to working together with you!